What's Going On With Aclaris Therapeutics Stock Today?
Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (eczema). The trial met the primary efficacy endpoint, the percent change from baseline in the Eczema…
#eczema #eczemaarea #bid #oncedaily #raghuramselvaraju #boobalanpachaiyappan #neutral #aclaris #dupixent #sanofisasny